CIBINQO DIN 02528398
Health Canada record
| Active ingredient(s) | ABROCITINIB 200 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | D11AH08 ABROCITINIB |
| Original market date | 29-Sep-2022 |
| Current status date | 29-Sep-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Pfizer Canada ULC — licence 100255, currently licensed, last inspection rating C (2023-08-07).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ABROCITINIB
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02528363 | CIBINQO | PFIZER CANADA ULC | Tablet | ABROCITINIB 50 MG | Marketed |
| 02528371 | CIBINQO | PFIZER CANADA ULC | Tablet | ABROCITINIB 100 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 28491 | 2022-06-29 | New Drug Submission (NDS) |
International API supply for ABROCITINIB
4 active FDA Drug Master Files.
Request a quote for CIBINQO